8AK Stock Chart & Stats
€46.64
-€0.30(-0.64%)
At close: 4:00 PM EDT
€46.64
-€0.30(-0.64%)
Day’s Range― - ―
52-Week Range€22.00 - €48.28
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€7.72B
Enterprise Value€6.95K
Total Cash (Recent Filing)€511.86M
Total Debt (Recent Filing)€1.58B
Price to Earnings (P/E)56.9
Beta0.74
Next Earnings
Jul 28, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding166,675,810
10 Day Avg. Volume8
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€48.56Price Target Upside4.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.34
Revenue Forecast (FY)€1.59B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Returning ProfitabilityAlkermes' very high gross margins (roughly mid-80s TTM) reflect a proprietary product mix and pricing power. Durable margin strength supports long-term operating leverage, funds R&D and launches, and underpins adjusted-EBITDA generation even as SG&A/R&D step up.
Broad Commercial Portfolio And LUMRYZ Launch MomentumSustained, multi-brand commercial growth (VIVITROL, ARISTADA, LYBALVI) plus an early, meaningful LUMRYZ launch establish diversified revenue streams. A multi-product commercial base reduces single-product risk and creates a structural platform to scale sales, supporting durable top-line expansion.
Positive Operating Cash Flow And Free Cash FlowPositive OCF and FCF provide self-funding for R&D, integration costs and debt reduction. Even with weaker momentum, TTM FCF near covers net income and supplies a sustainable internal funding source that enhances financial flexibility over the medium term.
Bears Say
Material Rise In Leverage After AcquisitionThe Avadel acquisition materially increased debt, reducing cash buffers and increasing refinancing and covenant risk. Higher leverage constrains strategic optionality, raises fixed charges and makes the company more sensitive to execution and revenue volatility over the next several years.
Weakening FCF And Cash QualityAlthough FCF remains positive, a sharp decline in cash-flow momentum and deteriorating OCF-to-income signals working-capital pressure or acquisition-related uses. Persistent weakness would limit deleveraging, reduce investment capacity, and raise sustainability concerns for payouts or buybacks.
Rising Opex And Margin Pressure (inventory, Gross-to-net)Elevated SG&A/R&D to support launches and integration, plus inventory step-up and widening gross-to-net, exert sustained margin pressure. These structural cost and net-price headwinds can compress operating leverage and require higher sales growth to restore prior net margin levels.
Alkermes News
8AK FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was €22.00 and its highest was €48.28 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is €7.72B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Jul 28, 2026 which is tomorrow.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on May 05, 2026. The company reported -€0.35 earnings per share for the quarter, beating the consensus estimate of -€0.478 by €0.128.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is -0.02.
How many shares outstanding does Alkermes have?
Alkermes has 166,675,810 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of -€0.35 in its last earnings report, beating expectations of -€0.478. Following the earnings report the stock price went up 2.81%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in DE:8AK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€48.56 (4.11% Upside)
€48.56 (4.11% Upside)
Blogger Sentiment
Bullish
DE:8AK Sentiment 85%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $687.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
104.52%
Trailing 12-Months
Company Description
Alkermes
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
8AK Company Deck
8AK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum, sizable year-over-year revenue growth (+38% for proprietary products), an encouraging early LUMRYZ launch with meaningful sales and patient growth, a material adjusted EBITDA beat, and clear pipeline progress with Phase III initiation and multiple new programs underway. Offsetting factors include a GAAP net loss and negative GAAP EBITDA in the quarter, elevated R&D and SG&A as programs scale and integration costs are realized, increased leverage and near-term margin pressure from inventory step-up and widening gross-to-net. On balance, the positives (revenue growth, LUMRYZ contribution, adjusted EBITDA beat, improved purchase price accounting and an expanding orexin pipeline) meaningfully outweigh the near-term financial and execution headwinds.View all DE:8AK earnings summaries8AK Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
8AK Stock 12 Month Forecast
Average Price Target
€48.56
▲(4.11% Upside)